Tremtelectogene empogeditemcel is under clinical development by Vor BioPharma and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tremtelectogene empogeditemcel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tremtelectogene empogeditemcel overview
Tremtelectogene empogeditemcel (VOR-33) is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), myelodysplastic syndrome. It is administered via parenteral route. The therapeutic candidate comprises allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC).It is developed based on eHSC technology.
It was also under development for the treatment of myeloproliferative neoplasm.
Vor BioPharma overview
Vor BioPharma (Vor Bio), a subsidiary of Puretech Health Plc, is a clinical-stage cell and genome engineering company that develops novel therapies for blood cancers. The company’s pipeline products include VCAR33 ALLO, VBP101, and VCAR33 for the indications of myelodysplastic syndromes and acute myeloid leukemia. It also leveraging its platform provides a CD33-CLL1 Treatment System. The company’s products are its proprietary treatment platform and its pipeline of therapies includes clinical trials for patients with relapsed and refractory Acute Myeloid Leukemia (AML). Vor Bio services are utilized by patients and caregivers, medical professionals, and investors in the biopharma sector. Vor Bio is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Tremtelectogene empogeditemcel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
